

Europe Generic Drugs Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Small Molecule and Biosimilar Products), Small Molecule (Capecitabine, Carboplatin, Asparaginase, Mitomycin, Doxorubicin, Methotrexate, Fluorouracil (5-FU) and Others), Drug Class (Central Nervous System, Cardiovascular, Urology, Rheumatology, Oncology, Hematology, and Others), Route Of Administration (Oral, Injectable, Topical and Others), Type (Prescription Drugs and Over-the-Counter Drugs), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and Country

https://marketpublishers.com/r/EFE62D38A2B0EN.html

Date: May 2025

Pages: 205

Price: US\$ 3,450.00 (Single User License)

ID: EFE62D38A2B0EN

Abstracts

Europe Generic Drugs Market Forecast to 2031 - Regional Analysis - by Product Type, Drug Class, Route of Administration, Type, and Distribution Channel," the market is projected to reach US\$ 114.03 billion by 2031 from US\$ 77.95 billion in 2024. The market is expected to register a CAGR of 5.8% during 2025-2031

The Europe generic drugs market forecast presented in this report can help stakeholders in this marketplace plan their growth strategies. The Rising Chronic Disease Burden and Increasing Demand for Cost-Effective Treatments and



Government Policies and Regulatory Support for Generics are the key factors propelling the Europe generic drugs Market growth.

Rising Chronic Disease Burden and Increasing Demand for Cost-Effective Treatments.

Europe is facing a significant increase in the prevalence of noncommunicable diseases (NCDs). 1 in 6 individuals succumb to these conditions before reaching the age of 70, with cardiovascular diseases, cancer, diabetes, and chronic respiratory illnesses being the primary contributors. As per the World Health Organization (WHO), in July 2024, ~64 million adults and ~300,000 children and adolescents had diabetes in the region, with one in three cases undiagnosed. By 2045, 1 in 10 Europeans may have diabetes, and Europe already carries the highest burden of type 1 diabetes globally. Also, the WHO reported over 4.47 million new cases and ~2 million cancer-related deaths in Europe in 2022.

According to the Organization for Economic Cooperation and Development (OECD) research conducted on OECD member countries in the European Union (EU), such as France, Spain, the Netherlands, Romania, and Portugal, published in February 2025, more than 70% of individuals in these countries living with multiple chronic conditions are prescribed with least three medications, and over one-third take four or more. France and the Czech Republic have the highest percentages of people with two or more chronic conditions, including mental health issues, at 77.24% and 70.13%, respectively.

The surging prevalence of chronic diseases in Europe is driving the healthcare systems and patients in seeking affordable solutions to manage long-term conditions. Generic medications offer cost-effective alternatives to brand-name drugs, making them attractive options for healthcare providers and patients. According to Generics and Biosimilar Initiative, in Europe, generic medicines are generally 20-80% cheaper than brand-name medicines, resulting in significant savings. 67% of dispensed medicine prescriptions are for generics, yet they account for just 29% of total expenditure on medicines. Without competition from generic manufacturers, maintaining this level of access would cost Europe an additional UD\$ 113.82 billion (€100 billion) each year.

According to an article published by the European Federation of Pharmaceutical Industries and Associations (EFPIA) in 2025, cancer spending varies from less than US\$ 169.75 (€150) per capita in Hungary, Croatia, Romania, Latvia, and Bulgaria to more than US\$ 452.68 (€400) in Germany and Switzerland. The high cost of biologics for cancer treatment is contributing to the growing adoption of biosimilars which are



relatively cost-effective options available in the market. According to WHO, biosimilars are ~ 60 % cheaper than their reference counterparts. Thus, the rising chronic disease burden is increasing the adoption of cost-effective generic medications for treatment, fueling the market growth.

Factor Hampering Europe generic drugs market

While generics offer a lower-cost alternative to branded medications, the pressure to lower prices to remain competitive forces manufacturers to sell their products at minimal profit. Generic drugs enter the market at a lower price point than branded drugs, often ranging 30-80% less. However, the sheer number of generic manufacturers that tend to enter the market once a patent expires, can lead to price conflicts. As more competitors launch their versions of a generic drug, the prices often drop substantially, thereby compressing profit margins. In 2023, Sandoz reported a 5% drop in operating income from its generics segment, even though revenues grew by 4%. The company highlighted price erosion in Europe, especially for antibiotics and oncology generics, as a major factor impacting its margins. Such impact on profit margins creates challenges for manufacturers to balance producing high-quality drugs while maintaining profitability. The reliance on high-volume sales to sustain profitability means that generic drug manufacturers face substantial risk during market saturation. If too many companies produce the same generic drug, the market becomes flooded with same generic drugs, and prices continue to drop, making it difficult for companies to recover their production and operational costs. In 2021, the UK NHS introduced cost-control measures that reduced reimbursements for generics by 8%. The Pharmaceutical Price Regulation Scheme (PPRS), which applies to branded and generic drugs, saw its ceiling lowered in 2022, requiring generics manufacturers to provide greater rebates for NHS drugs. As of 2023, the rebate to the NHS from generics producers was estimated to reach nearly US\$ 2.64 billion (?2 billion), reflecting the increasing pressure on pricing. This pressure is challenging for small and mid-sized generic pharmaceutical companies, which may struggle to compete with prominent players that have the resources to absorb lower margins. The entry of large pharmaceutical firms into the generic drug space can exacerbate this price competition. These firms have more resources to lower prices and maintain profitability due to their economies of scale, making it difficult for smaller generic manufacturers to compete. In markets with price pressure, generic drug manufacturers may be forced to prioritize cost-cutting measures in production, compromising on aspects such as quality control or innovation. This prioritization can lead to potential concerns around the safety and efficacy of generics, though regulatory bodies such as the EMA have measures in place to prevent such issues. In conclusion, the intense price competition and low profit margins can create a challenging



environment for manufacturers. Companies must navigate these pressures carefully to maintain sustainability and continue to provide affordable alternatives to branded medications.

Based on product type, the Europe Generic Drugs market is bifurcated into Small Molecule (Fluorouracil (5-FU), Methotrexate, Doxorubicin, Mitomycin, Asparaginase, Carboplatin, Capecitabine, Others) and Biosimilar Products. The Small Molecule segment held a larger share of the Europe Generic Drugs market in 2024

By drug class, the Europe Generic Drugs market is segmented into Drug Class (Central Nervous System, Cardiovascular, Urology, Rheumatology, Oncology, Hematology and Others). The Others segment held the largest share of the Europe Generic Drugs market in 2024.

In terms of route of administration, the Europe Generic Drugs market is segmented into Route of Administration (Oral, Injectable, Topical and Others). The Oral segment held the largest share in the Europe Generic Drugs market in 2024.

By Type, the market is bifurcated into Type (Prescription Drugs and Over-the-Counter Drugs). The Prescription Drugs segment held a larger share of the Europe Generic Drugs market in 2024.

Based on distribution channel, the market is segmented into Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies). The Hospital Pharmacies segment held the largest share of the Europe Generic Drugs market in 2024.

A few of the major primary and secondary sources referred to while preparing the report on the Europe Generic Drugs Market are Teva Pharmaceutical Industries, Viatris Inc, Dr. Reddy's Laboratories Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, AbbVie Inc, AstraZeneca Plc, Sanofi SA, Aurobindo Pharma Ltd, Glenmark Pharmaceuticals Ltd, Hikma Pharmaceuticals Plc, Cipla Ltd, GSK Plc, Eli Lilly and Co, medac Pharma LLP, Lupin Ltd.

Reason to buy



Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe Generic Drugs Market.

Highlights key business priorities in order to assist companies to realign their business strategies.

The key findings and recommendations highlight crucial progressive industry trends in the Europe Generic Drugs Market, thereby allowing players across the value chain to develop effective long-term strategies.

Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

Scrutinize in-depth market trends and outlook coupled with the factors driving the Europe Generic Drugs Market, as well as those hindering it.

Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.



Contents

1. INTRODUCTION

- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation

2. EXECUTIVE SUMMARY

2.1 Analyst Market Outlook

3. RESEARCH METHODOLOGY

- 3.1 Secondary Research
- 3.2 Primary Research
 - 3.2.1 Hypothesis formulation:
 - 3.2.2 Macro-economic factor analysis:
 - 3.2.3 Developing base number:
 - 3.2.4 Data Triangulation:
 - 3.2.5 Country level data:

4. EUROPE GENERIC DRUGS MARKET LANDSCAPE

- 4.1 Overview
- 4.2 PEST Analysis
- 4.3 Average Selling Price, 2024
- 4.4 Branded Drugs Patent expiry date:
- 4.5 Pipeline Analysis:

5. EUROPE GENERIC DRUGS MARKET - KEY MARKET DYNAMICS

- 5.1 Europe Generic Drugs Market Key Market Dynamics
- 5.2 Market Drivers
- 5.2.1 Rising Chronic Disease Burden and Increasing Demand for Cost-Effective
- 5.2.2 Government Policies and Regulatory Support for Generics
- 5.3 Market Restraints
 - 5.3.1 Intense Price Competition and Thin Profit Margins
- 5.4 Market Opportunities



- 5.4.1 Patent Expiry and Loss of Market Exclusivity
- 5.5 Future Trends
 - 5.5.1 Expansion of Biosimilars
- 5.6 Impact of Drivers and Restraints:

6. EUROPE GENERIC DRUGS MARKET ANALYSIS

- 6.1 Europe Generic Drugs Market Revenue (US\$ Million), 2021-2031
- 6.2 Europe Generic Drugs Market Forecast and Analysis

7. EUROPE GENERIC DRUGS MARKET ANALYSIS - BY PRODUCT TYPE

- 7.1 Small Molecule
 - 7.1.1 Overview
- 7.1.2 Small Molecule: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)
- 7.2 Biosimilar Products
 - 7.2.1 Overview
- 7.2.2 Biosimilar Products: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)

8. EUROPE GENERIC DRUGS MARKET ANALYSIS - BY DRUG CLASS

- 8.1 Central Nervous System
 - 8.1.1 Overview
- 8.1.2 Central Nervous System: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)
- 8.2 Cardiovascular
 - 8.2.1 Overview
- 8.2.2 Cardiovascular: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)
- 8.3 Urology
 - 8.3.1 Overview
- 8.3.2 Urology: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)
- 8.4 Rheumatology
 - 8.4.1 Overview
- 8.4.2 Rheumatology: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)



- 8.5 Oncology
 - 8.5.1 Overview
- 8.5.2 Oncology: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)
- 8.6 Hematology
 - 8.6.1 Overview
- 8.6.2 Hematology: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)
- 8.7 Others
 - 8.7.1 Overview
- 8.7.2 Others: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)

9. EUROPE GENERIC DRUGS MARKET ANALYSIS - BY ROUTE OF ADMINISTRATION

- 9.1 Oral
 - 9.1.1 Overview
- 9.1.2 Oral: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)
- 9.2 Injectable
 - 9.2.1 Overview
- 9.2.2 Injectable: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)
- 9.3 Topical
 - 9.3.1 Overview
- 9.3.2 Topical: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)
- 9.4 Others
 - 9.4.1 Overview
- 9.4.2 Others: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)

10. EUROPE GENERIC DRUGS MARKET ANALYSIS - BY TYPE

- 10.1 Prescription Drugs
 - 10.1.1 Overview
- 10.1.2 Prescription Drugs: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)



- 10.2 Over-the-Counter Drugs
 - 10.2.1 Overview
- 10.2.2 Over-the-Counter Drugs: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)

11. EUROPE GENERIC DRUGS MARKET ANALYSIS - BY DISTRIBUTION CHANNEL

- 11.1 Hospital Pharmacies
- 11.1.1 Overview
- 11.1.2 Hospital Pharmacies: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)
- 11.2 Retail Pharmacies
 - 11.2.1 Overview
- 11.2.2 Retail Pharmacies: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)
- 11.3 Online Pharmacies
 - 11.3.1 Overview
- 11.3.2 Online Pharmacies: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)

12. EUROPE GENERIC DRUGS MARKET - COUNTRY ANALYSIS

- 12.1 Europe
 - 12.1.1 Europe Generic Drugs Market Breakdown by Countries
 - 12.1.2 Europe Generic Drugs Market Revenue and Forecast and Analysis by Country
- 12.1.2.1 Europe Generic Drugs Market Revenue and Forecast and Analysis by Country
- 12.1.2.2 Germany: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)
 - 12.1.2.2.1 Germany: Europe Generic Drugs Market Breakdown by Product Type
 - 12.1.2.2.2 Germany: Europe Generic Drugs Market Breakdown by Small Molecule
 - 12.1.2.2.3 Germany: Europe Generic Drugs Market Breakdown by Drug Class
- 12.1.2.2.4 Germany: Europe Generic Drugs Market Breakdown by Route Of Administration
 - 12.1.2.2.5 Germany: Europe Generic Drugs Market Breakdown by Type
- 12.1.2.2.6 Germany: Europe Generic Drugs Market Breakdown by Distribution Channel
 - 12.1.2.3 France: Europe Generic Drugs Market Revenue and Forecast to 2031



(US\$ Million)

- 12.1.2.3.1 France: Europe Generic Drugs Market Breakdown by Product Type
- 12.1.2.3.2 France: Europe Generic Drugs Market Breakdown by Small Molecule
- 12.1.2.3.3 France: Europe Generic Drugs Market Breakdown by Drug Class
- 12.1.2.3.4 France: Europe Generic Drugs Market Breakdown by Route Of Administration
 - 12.1.2.3.5 France: Europe Generic Drugs Market Breakdown by Type
- 12.1.2.3.6 France: Europe Generic Drugs Market Breakdown by Distribution Channel
- 12.1.2.4 United Kingdom: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)
- 12.1.2.4.1 United Kingdom: Europe Generic Drugs Market Breakdown by Product Type
- 12.1.2.4.2 United Kingdom: Europe Generic Drugs Market Breakdown by Small Molecule
- 12.1.2.4.3 United Kingdom: Europe Generic Drugs Market Breakdown by Drug Class
- 12.1.2.4.4 United Kingdom: Europe Generic Drugs Market Breakdown by Route Of Administration
 - 12.1.2.4.5 United Kingdom: Europe Generic Drugs Market Breakdown by Type
- 12.1.2.4.6 United Kingdom: Europe Generic Drugs Market Breakdown by Distribution Channel
- 12.1.2.5 Italy: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)
 - 12.1.2.5.1 Italy: Europe Generic Drugs Market Breakdown by Product Type
 - 12.1.2.5.2 Italy: Europe Generic Drugs Market Breakdown by Small Molecule
 - 12.1.2.5.3 Italy: Europe Generic Drugs Market Breakdown by Drug Class
- 12.1.2.5.4 Italy: Europe Generic Drugs Market Breakdown by Route Of Administration
 - 12.1.2.5.5 Italy: Europe Generic Drugs Market Breakdown by Type
 - 12.1.2.5.6 Italy: Europe Generic Drugs Market Breakdown by Distribution Channel
- 12.1.2.6 Spain: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)
 - 12.1.2.6.1 Spain: Europe Generic Drugs Market Breakdown by Product Type0
 - 12.1.2.6.2 Spain: Europe Generic Drugs Market Breakdown by Small Molecule1
 - 12.1.2.6.3 Spain: Europe Generic Drugs Market Breakdown by Drug Class2
- 12.1.2.6.4 Spain: Europe Generic Drugs Market Breakdown by Route Of Administration3
 - 12.1.2.6.5 Spain: Europe Generic Drugs Market Breakdown by Type3



- 12.1.2.6.6 Spain: Europe Generic Drugs Market Breakdown by Distribution Channel4
- 12.1.2.7 Poland: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)5
 - 12.1.2.7.1 Poland: Europe Generic Drugs Market Breakdown by Product Type6
 - 12.1.2.7.2 Poland: Europe Generic Drugs Market Breakdown by Small Molecule7
 - 12.1.2.7.3 Poland: Europe Generic Drugs Market Breakdown by Drug Class8
- 12.1.2.7.4 Poland: Europe Generic Drugs Market Breakdown by Route Of Administration9
 - 12.1.2.7.5 Poland: Europe Generic Drugs Market Breakdown by Type9
- 12.1.2.7.6 Poland: Europe Generic Drugs Market Breakdown by Distribution Channel0
- 12.1.2.8 Nordic Region: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)1
- 12.1.2.8.1 Nordic Region: Europe Generic Drugs Market Breakdown by Product Type2
- 12.1.2.8.2 Nordic Region: Europe Generic Drugs Market Breakdown by Small Molecule3
 - 12.1.2.8.3 Nordic Region: Europe Generic Drugs Market Breakdown by Drug Class4
- 12.1.2.8.4 Nordic Region: Europe Generic Drugs Market Breakdown by Route Of Administration5
 - 12.1.2.8.5 Nordic Region: Europe Generic Drugs Market Breakdown by Type6
- 12.1.2.8.6 Nordic Region: Europe Generic Drugs Market Breakdown by Distribution Channel7
- 12.1.2.9 Rest of Europe: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)8
- 12.1.2.9.1 Rest of Europe: Europe Generic Drugs Market Breakdown by Product Type9
- 12.1.2.9.2 Rest of Europe: Europe Generic Drugs Market Breakdown by Small Molecule0
- 12.1.2.9.3 Rest of Europe: Europe Generic Drugs Market Breakdown by Drug Class1
- 12.1.2.9.4 Rest of Europe: Europe Generic Drugs Market Breakdown by Route Of Administration2
 - 12.1.2.9.5 Rest of Europe: Europe Generic Drugs Market Breakdown by Type3
- 12.1.2.9.6 Rest of Europe: Europe Generic Drugs Market Breakdown by Distribution Channel3

13. COMPETITIVE LANDSCAPE5



- 13.1 Heat Map Analysis by Key Players5
- 13.2 Company Market Share Analysis, 20245

14. INDUSTRY LANDSCAPE6

- 14.1 Overview6
- 14.2 Market Initiative6
- 14.3 Merger and Acquisition6

15. COMPANY PROFILES7

16. APPENDIX8

- 16.1 Glossary of Terms8
- 16.2 About The Insight Partners9



List Of Tables

LIST OF TABLES

- Table 1. Europe Generic Drugs Market Segmentation
- Table 2. Condition: Epilepsy, Fibromyalgia, Generalized Anxiety Disorder, among others
- Table 3. Condition: Erectile Dysfunction
- Table 4. Condition: Cardiovascular Disease, High Cholesterol
- Table 5. Condition: Asthma, Chronic Obstructive Pulmonary Disease
- Table 6. Condition: Diabetes Type I and II
- Table 7. Europe Generic Drugs Market Revenue, 2021 -2024 (US\$ Million)
- Table 8. Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million)
- Table 9. Europe Generic Drugs Market Revenue, 2021 2024 (US\$ Million) By Product Type
- Table 10. Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) By Product Type
- Table 11. Europe Generic Drugs Market Revenue, 2021 2024 (US\$ Million) By Drug Class
- Table 12. Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) By Drug Class
- Table 13. Europe Generic Drugs Market Revenue, 2021 2024 (US\$ Million) By Route Of Administration
- Table 14. Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) By Route Of Administration
- Table 15. Europe Generic Drugs Market Revenue, 2021 2024 (US\$ Million) By Type
- Table 16. Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) By Type
- Table 17. Europe Generic Drugs Market Revenue, 2021 2024 (US\$ Million) By Distribution Channel
- Table 18. Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) By Distribution Channel
- Table 19. Europe Generic Drugs Market Revenue, 2021 2024 (US\$ Million) by Country
- Table 20. Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) by Country
- Table 21. Germany: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by Product Type
- Table 22. Germany: Europe Generic Drugs Market Revenue, 2025 2031 (US\$



Million) - by Product Type

Table 23. Germany: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$ Million)

- by Small Molecule

Table 24. Germany: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$

Million) - by Small Molecule

Table 25. Germany: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$ Million)

- by Drug Class

Table 26. Germany: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$

Million) - by Drug Class

Table 27. Germany: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$ Million)

- by Route Of Administration

Table 28. Germany: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$

Million) - by Route Of Administration

Table 29. Germany: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$ Million)

- by Type

Table 30. Germany: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$

Million) - by Type

Table 31. Germany: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$ Million)

- by Distribution Channel

Table 32. Germany: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$

Million) - by Distribution Channel

Table 33. France: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$ Million) -

by Product Type

Table 34. France: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$ Million) -

by Product Type

Table 35. France: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$ Million) -

by Small Molecule

Table 36. France: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$ Million) -

by Small Molecule

Table 37. France: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$ Million) -

by Drug Class

Table 38. France: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$ Million) -

by Drug Class

Table 39. France: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$ Million) -

by Route Of Administration

Table 40. France: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$ Million) -

by Route Of Administration

Table 41. France: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$ Million) -

by Type



- Table 42. France: Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) by Type
- Table 43. France: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by Distribution Channel
- Table 44. France: Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) by Distribution Channel
- Table 45. United Kingdom: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by Product Type
- Table 46. United Kingdom: Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) by Product Type
- Table 47. United Kingdom: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by Small Molecule
- Table 48. United Kingdom: Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) by Small Molecule
- Table 49. United Kingdom: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by Drug Class
- Table 50. United Kingdom: Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) by Drug Class
- Table 51. United Kingdom: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by Route Of Administration
- Table 52. United Kingdom: Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) by Route Of Administration
- Table 53. United Kingdom: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by Type
- Table 54. United Kingdom: Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) by Type
- Table 55. United Kingdom: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by Distribution Channel
- Table 56. United Kingdom: Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) by Distribution Channel
- Table 57. Italy: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by Product Type
- Table 58. Italy: Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) by Product Type
- Table 59. Italy: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by Small Molecule
- Table 60. Italy: Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) by Small Molecule
- Table 61. Italy: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by



Drug Class

Table 62. Italy: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$ Million) - by Drug Class

Table 63. Italy: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$ Million) - by Route Of Administration

Table 64. Italy: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$ Million) - by Route Of Administration

Table 65. Italy: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$ Million) - by Type

Table 66. Italy: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$ Million) - by Type

Table 67. Italy: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$ Million) - by Distribution Channel

Table 68. Italy: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$ Million) - by Distribution Channel

Table 69. Spain: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$ Million) - by Product Type0

Table 70. Spain: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$ Million) - by Product Type0

Table 71. Spain: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$ Million) - by Small Molecule1

Table 72. Spain: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$ Million) - by Small Molecule1

Table 73. Spain: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$ Million) - by Drug Class2

Table 74. Spain: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$ Million) - by Drug Class2

Table 75. Spain: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$ Million) - by Route Of Administration3

Table 76. Spain: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$ Million) - by Route Of Administration3

Table 77. Spain: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$ Million) - by Type3

Table 78. Spain: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$ Million) - by Type4

Table 79. Spain: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$ Million) - by Distribution Channel4

Table 80. Spain: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$ Million) - by Distribution Channel4



- Table 81. Poland: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by Product Type6
- Table 82. Poland: Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) by Product Type6
- Table 83. Poland: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by Small Molecule7
- Table 84. Poland: Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) by Small Molecule7
- Table 85. Poland: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by Drug Class8
- Table 86. Poland: Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) by Drug Class8
- Table 87. Poland: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by Route Of Administration9
- Table 88. Poland: Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) by Route Of Administration9
- Table 89. Poland: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by Type9
- Table 90. Poland: Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) by Type0
- Table 91. Poland: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by Distribution Channel0
- Table 92. Poland: Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) by Distribution Channel0
- Table 93. Nordic Region: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by Product Type2
- Table 94. Nordic Region: Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) by Product Type3
- Table 95. Nordic Region: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by Small Molecule3
- Table 96. Nordic Region: Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) by Small Molecule4
- Table 97. Nordic Region: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by Drug Class4
- Table 98. Nordic Region: Europe Generic Drugs Market Revenue, 2025 2031 (US\$ Million) by Drug Class5
- Table 99. Nordic Region: Europe Generic Drugs Market Revenue, 2021 -2031 (US\$ Million) by Route Of Administration5
- Table 100. Nordic Region: Europe Generic Drugs Market Revenue, 2025 2031 (US\$



Million) - by Route Of Administration6

Table 101. Nordic Region: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$

Million) - by Type6

Table 102. Nordic Region: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$

Million) - by Type6

Table 103. Nordic Region: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$

Million) - by Distribution Channel7

Table 104. Nordic Region: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$

Million) - by Distribution Channel7

Table 105. Rest of Europe: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$

Million) - by Product Type9

Table 106. Rest of Europe: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$

Million) - by Product Type9

Table 107. Rest of Europe: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$

Million) - by Small Molecule0

Table 108. Rest of Europe: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$

Million) - by Small Molecule0

Table 109. Rest of Europe: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$

Million) - by Drug Class1

Table 110. Rest of Europe: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$

Million) - by Drug Class1

Table 111. Rest of Europe: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$

Million) - by Route Of Administration2

Table 112. Rest of Europe: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$

Million) - by Route Of Administration2

Table 113. Rest of Europe: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$

Million) - by Type3

Table 114. Rest of Europe: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$

Million) - by Type3

Table 115. Rest of Europe: Europe Generic Drugs Market - Revenue, 2021 -2031 (US\$

Million) - by Distribution Channel3

Table 116. Rest of Europe: Europe Generic Drugs Market - Revenue, 2025 - 2031 (US\$

Million) - by Distribution Channel4

Table 117. Heat Map Analysis by Key Players5

Table 118. Glossary of Terms, Pharmaceutical Market8



List Of Figures

LIST OF FIGURES

- Figure 1. Europe Generic Drugs Market Segmentation, by Country
- Figure 2. PEST Analysis
- Figure 3. Impact Analysis of Drivers and Restraints
- Figure 4. Europe Generic Drugs Market Revenue (US\$ Million), 2021-2031
- Figure 5. Europe Generic Drugs Market Share (%) by Product Type, 2024 and 2031
- Figure 6. Small Molecule: Europe Generic Drugs Market- Revenue and Forecast to 2031 (US\$ Million)
- Figure 7. Biosimilar Products: Europe Generic Drugs Market- Revenue and Forecast to 2031 (US\$ Million)
- Figure 8. Europe Generic Drugs Market Share (%) by Drug Class, 2024 and 2031
- Figure 9. Central Nervous System: Europe Generic Drugs Market- Revenue and Forecast to 2031 (US\$ Million)
- Figure 10. Cardiovascular: Europe Generic Drugs Market- Revenue and Forecast to 2031 (US\$ Million)
- Figure 11. Urology: Europe Generic Drugs Market- Revenue and Forecast to 2031 (US\$ Million)
- Figure 12. Rheumatology: Europe Generic Drugs Market- Revenue and Forecast to 2031 (US\$ Million)
- Figure 13. Oncology: Europe Generic Drugs Market- Revenue and Forecast to 2031 (US\$ Million)
- Figure 14. Hematology: Europe Generic Drugs Market- Revenue and Forecast to 2031 (US\$ Million)
- Figure 15. Others: Europe Generic Drugs Market- Revenue and Forecast to 2031 (US\$ Million)
- Figure 16. Europe Generic Drugs Market Share (%) by Route Of Administration, 2024 and 2031
- Figure 17. Oral: Europe Generic Drugs Market- Revenue and Forecast to 2031 (US\$ Million)
- Figure 18. Injectable: Europe Generic Drugs Market- Revenue and Forecast to 2031 (US\$ Million)
- Figure 19. Topical: Europe Generic Drugs Market- Revenue and Forecast to 2031 (US\$ Million)
- Figure 20. Others: Europe Generic Drugs Market- Revenue and Forecast to 2031 (US\$ Million)
- Figure 21. Europe Generic Drugs Market Share (%) by Type, 2024 and 2031



- Figure 22. Prescription Drugs: Europe Generic Drugs Market- Revenue and Forecast to 2031 (US\$ Million)
- Figure 23. Over-the-Counter Drugs: Europe Generic Drugs Market- Revenue and Forecast to 2031 (US\$ Million)
- Figure 24. Europe Generic Drugs Market Share (%) by Distribution Channel, 2024 and 2031
- Figure 25. Hospital Pharmacies: Europe Generic Drugs Market- Revenue and Forecast to 2031 (US\$ Million)
- Figure 26. Retail Pharmacies: Europe Generic Drugs Market- Revenue and Forecast to 2031 (US\$ Million)
- Figure 27. Online Pharmacies: Europe Generic Drugs Market- Revenue and Forecast to 2031 (US\$ Million)
- Figure 28. Europe Generic Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)
- Figure 29. Germany: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)
- Figure 30. France: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)
- Figure 31. United Kingdom: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)
- Figure 32. Italy: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)
- Figure 33. Spain: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)
- Figure 34. Poland: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)5
- Figure 35. Nordic Region: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)1
- Figure 36. Rest of Europe: Europe Generic Drugs Market Revenue and Forecast to 2031 (US\$ Million)8
- Figure 37. Company Market Share Analysis, 20245
- Figure 21. Europe Regenerative Dentistry Market Share (%) by End-user, 2024 and 2031
- Figure 22. Hospitals: Europe Regenerative Dentistry Market- Revenue and Forecast to 2031 (US\$ Million)
- Figure 23. Dental Clinics: Europe Regenerative Dentistry Market- Revenue and Forecast to 2031 (US\$ Million)
- Figure 24. Others: Europe Regenerative Dentistry Market- Revenue and Forecast to



2031 (US\$ Million)

Figure 25. Europe Regenerative Dentistry Market Breakdown by Key Countries, 2024 and 2031 (%)

Figure 26. Germany: Europe Regenerative Dentistry Market - Revenue and Forecast to 2031 (US\$ Million)

Figure 27. United Kingdom: Europe Regenerative Dentistry Market - Revenue and Forecast to 2031 (US\$ Million)

Figure 28. France: Europe Regenerative Dentistry Market - Revenue and Forecast to 2031 (US\$ Million)

Figure 29. Italy: Europe Regenerative Dentistry Market - Revenue and Forecast to 2031 (US\$ Million)

Figure 30. Spain: Europe Regenerative Dentistry Market - Revenue and Forecast to 2031 (US\$ Million)

Figure 31. Rest of Europe: Europe Regenerative Dentistry Market - Revenue and Forecast to 2031 (US\$ Million)



I would like to order

Product name: Europe Generic Drugs Market Size and Forecast (2021 - 2031), Regional Share, Trend,

and Growth Opportunity Analysis Report Coverage: By Product Type (Small Molecule and Biosimilar Products), Small Molecule (Capecitabine, Carboplatin, Asparaginase, Mitomycin, Doxorubicin, Methotrexate, Fluorouracil (5-FU) and Others), Drug Class (Central Nervous System, Cardiovascular, Urology, Rheumatology, Oncology, Hematology, and Others), Route Of Administration (Oral, Injectable, Topical and Others), Type (Prescription Drugs and Over-the-Counter Drugs), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and Country

Product link: https://marketpublishers.com/r/EFE62D38A2B0EN.html

Price: US\$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/EFE62D38A2B0EN.html